Of note is that at least one other ERBB2-amplified breast cancer in this cohort was known to have developed RET amplification after it had acquired resistance to multiple HER2-targeted agents and that this was associated with overexpression of RET in the tumor (* in Fig. 1a and Supplementary Fig. 4c). The gene discussed is ERBB2; the disease is breast carcinoma.